Clinical Trials: Laboratory Data Reconciliation

CAPA Framework – Steps in Reconciling Lab and EDC Data

Posted on digi By digi

In modern clinical trials, electronic data capture (EDC) systems and laboratory information management systems (LIMS) operate as distinct yet interdependent platforms. Data discrepancies between these systems can lead to delayed submissions, data integrity questions, or even rejection of regulatory filings. Regulatory agencies like the FDA and EMA require sponsors to have well-documented procedures for reconciling lab and EDC data and correcting issues using a robust CAPA framework.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

How to Achieve Real-Time Reconciliation Dashboards – FDA/EMA Ready Guide

Posted on digi By digi

In clinical research, the timely reconciliation of laboratory data with electronic data capture (EDC) systems is critical for ensuring regulatory compliance and maintaining data integrity. Traditionally, reconciliation has been a manual, periodic process. However, sponsors and CROs are now increasingly adopting real-time dashboards to streamline this process, reduce errors, and proactively manage discrepancies. These tools offer high visibility into lab–EDC mismatches and support risk-based monitoring strategies.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Case Studies on Data Discrepancy Trending Between Lab and EDC Systems

Posted on digi By digi

Discrepancies between laboratory data and Electronic Data Capture (EDC) systems are a major concern in clinical research. These mismatches can compromise data integrity, delay trial timelines, and raise red flags during regulatory inspections. More importantly, repeated discrepancies signal systemic issues, necessitating robust trending and CAPA mechanisms.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Building SOPs for Handling Data Discrepancies Between Lab and Site Systems

Posted on digi By digi

In clinical trials, data discrepancies between laboratory systems and site-collected data are a persistent challenge. These mismatches—ranging from missing values to differing units or delayed transfers—can raise significant compliance risks. The FDA, EMA, and ICH E6(R2) emphasize the need for formalized SOPs to address and reconcile such inconsistencies.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

CAPA Playbook – Audit-Proofing the Lab and Site Reconciliation Process

Posted on digi By digi

The reconciliation of data between laboratory systems and site-collected records is a critical aspect of data integrity in clinical trials. Discrepancies, if unmanaged, can compromise subject safety, trial outcomes, and regulatory compliance. Regulatory authorities such as the FDA and EMA expect robust CAPA (Corrective and Preventive Action) procedures to be implemented when such discrepancies occur.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Inspection Readiness Playbook – Managing Protocol Deviations in Reconciliation

Posted on digi By digi

In clinical trials, reconciliation between laboratory results and electronic data capture (EDC) systems is critical for ensuring data integrity and regulatory compliance. When this reconciliation is delayed or incomplete, it can result in protocol deviations that impact patient safety and data quality. Regulatory authorities, including the FDA and EMA, view such deviations as serious non-compliances if not addressed appropriately.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

How to Achieve Role-Based Access Control in Reconciliation Systems

Posted on digi By digi

Role-Based Access Control (RBAC) is critical to safeguarding laboratory and EDC data in clinical trials. As reconciliation involves data entry, validation, and resolution of discrepancies across systems, only authorized users must access specific data elements. Without proper RBAC, unauthorized access could lead to untraceable changes, audit trail gaps, or data integrity violations — all of which are flagged during inspections by regulatory authorities such as the FDA or EMA.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

CAPA Framework – Trending Errors in Reconciliation and Root Cause Analysis

Posted on digi By digi

Data reconciliation between Laboratory Information Management Systems (LIMS) and Electronic Data Capture (EDC) platforms is a cornerstone of clinical trial quality assurance. Discrepancies may arise due to sample labeling mismatches, data entry errors, timing variances, or incorrect transfer protocols. While single-instance deviations may be managed, recurring discrepancies or trending errors indicate systemic issues that demand deeper investigation through a CAPA (Corrective and Preventive Action) framework.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Building a Centralized Reconciliation Log for Multi-Site Trials

Posted on digi By digi

In multi-site clinical trials, laboratory results and clinical data are often managed across diverse geographies, time zones, vendors, and systems. This fragmented landscape increases the likelihood of discrepancies between lab results, source documents, and EDC entries. Without a centralized reconciliation log, resolving these discrepancies becomes cumbersome, error-prone, and non-compliant with regulatory expectations.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation